Souha Kanj

Prof. Souha Kanj

American University of Beirut Medical Center
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
ETEvelina Tacconelli
Evelina Tacconelli
ECElena Carrara
Elena Carrara
ASAlessia Savoldi
Alessia Savoldi
SHStephan Harbarth
Stephan Harbarth
MMMarc Mendelson
Marc Mendelson
AZAnna Zorzet
Anna Zorzet

29 July 2015 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EBElie F. Berbari
Elie F. Berbari
Souha KanjSouha Kanj
Souha Kanj
TKTodd J. Kowalski
Todd J. Kowalski
RDRabih O. Darouiche
Rabih O. Darouiche
AWAndreas F. Widmer
Andreas F. Widmer
DODouglas R. Osmon
Douglas R. Osmon
These guidelines are intended for use by infectious disease specialists, orthopedic surgeons, neurosurgeons, radiologists, and other healthcare professionals who care for patients with native vertebral osteomyelitis (NVO). They include evidence and opinion-based recommendations for the diagnosis and management of patients with NVO treated with antimicrobial therapy, with or without surgical intervention.

11 September 2018 in JAMA
Verified
Journal Article
Open access
PDF file
PHPatrick Harris
Patrick Harris
PTPaul A. Tambyah
Paul A. Tambyah
DLDavid C. Lye
David C. Lye
YMYin Mo
Yin Mo
TLTau H. Lee
Tau H. Lee
F(for the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
for the MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN)
Quiz Ref ID Gram-negative bacteria that produce extended-spectrum β-lactamase (ESBL) enzymes are a global public health concern.1 Based on national surveillance data from 2011, the US Centers for Disease Control and Prevention estimated that ESBL producers accounted for at least 26 000 infections and 1700 deaths annually.2 A key feature of ESBL-producing Enterobacteriaceae is phenotypic resistance to oxyiminocephalosporins, in addition to penicillins.3 ESBL producers are increasingly commonplace in both community and health care settings.4 Carbapenems have been regarded as the treatment of choice for serious infections caused by ESBL producers.3,5 However, increased use of carbapenems may select for carbapenem resistance in gram-negative bacilli,6,7 which currently represents the greatest threat in terms of antibiotic resistance.

1 July 2016 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
FMFrancisco M Marty
Francisco M Marty
LOLuis Ostrosky-Zeichner
Luis Ostrosky-Zeichner
OCOliver A. Cornely
Oliver A. Cornely
KMKathleen M Mullane
Kathleen M Mullane
JPJohn R Perfect
John R Perfect
MVMaria J G T Vehreschild
Maria J G T Vehreschild

1 June 2012 in American Journal of Infection Control
Verified
Journal Article
Closed access
VRVictor D. Rosenthal
Victor D. Rosenthal
HBHu Bijie
Hu Bijie
DMDennis G. Maki
Dennis G. Maki
YMYatin Mehta
Yatin Mehta
AAAnucha Apisarnthanarak
Anucha Apisarnthanarak
KJKushlani Jayatilleke
Kushlani Jayatilleke

21 March 2024 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
CLCornelia Lass-Flörl
Cornelia Lass-Flörl
Souha KanjSouha Kanj
Souha Kanj
NGNelesh P. Govender
Nelesh P. Govender
GTGeorge R. Thompson
George R. Thompson
LZLuis Ostrosky- Zeichner
Luis Ostrosky- Zeichner
MGMiriam Alisa Govrins
Miriam Alisa Govrins